Express Pharma
Home  »  AYUSH  »  154 misleading ads related to AYUSH remedies for COVID-19 till August 2020: Dr Harsh Vardhan  

154 misleading ads related to AYUSH remedies for COVID-19 till August 2020: Dr Harsh Vardhan  

Public advisories and guidelines issued for AYUSH remedies to treat COVID-19 infections, powers of regulation and quality control of these drugs and formulations are vested with the state governments

0 7,391
Read Article

Dr Harsh Vardhan, Minister of Health and Family Welfare, in a written reply in the Lok Sabha informed that the Ministry of AYUSH has received 154 misleading advertisements related to AYUSH claims for COVID-19 from different parts of the country till August 2020.

In this regard, Ministry of AYUSH has issued directives to the State/UT authorities to initiate necessary action against the defaulters and alleged manufacturers/ advertisers acting in contravention of the provisions of Drugs and Cosmetics Act, 1940 & Rules there under and Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules there under and to send the details of the clinical trials of AYUSH medicines claimed for the prevention or treatment of COVID-19 for verification.  Ministry of AYUSH has also issued public advisories and guidelines for the practitioners about the use of AYUSH remedies to meet the challenge of COVID-19, details are available in the Ministry’s website www.ayush.gov.in

He informed that a number of medicinal products for immunity and health promotion have come in the market after Ministry of AYUSH issued public advisories of AYUSH-based healthcare during COVID-19 outbreak and promulgated a generic formulation called Ayush Kwath/Ayush Kudineer/Ayush Joshanda comprising Tulsi (Ocimum sanctum) leaves: 4 parts, Dalchini (Cinnamomumzeylanicum) stem bark: 2 parts, Sunthi (Zingiberofficinale) rhizome: 2 parts and Krishna Marich (Piper nigrum) fruits:1 part.  State Licensing Authorities have started granting license or approval for commercial manufacturing of such formulations under the provisions of Drugs and Cosmetics Rules, 1945 as applicable to Ayurvedic, Siddha and Unani (ASU) drugs.

Dr Vardhan also said that instances of adverse effects due to consumption of above-mentioned immunity-boosting drugs are not reported from the States/UTs. But, the incidences of COVID-19 related exaggerated claims and misleading advertisements of AYUSH drugs have been reported by pharmacovigilance centres and forwarded to the concerned State Licensing Authorities/Drug Controllers and individual advertisers/manufacturers for corrective action

As per the provisions of Drugs & Cosmetics Act, 1940 and Rules thereunder, approval of Ministry of AYUSH is not required to manufacture for sale of Ayurvedic, Siddha and Unani drugs and such medicinal formulations. Powers of regulation and quality control of these drugs and formulations are vested with the State Governments, for which State Licensing Authorities/Drug Controllers are appointed.

(Source: PIB)

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image